The LR3 in IGF-1 LR3 is two modifications, and both exist to defeat the same obstacle. Native IGF-1 circulates almost entirely bound to binding proteins, which control where and whether it acts. Long R3 IGF-1 carries a substitution and an extension that together reduce that binding dramatically. Understanding what was changed explains both why the analogue behaves differently and why comparing the two in an assay is harder than it looks.
What native IGF-1 is
A 70-residue single-chain polypeptide, structurally related to proinsulin, acting principally at the IGF-1 receptor — a receptor tyrosine kinase rather than a GPCR, which puts it in a different signalling category from most compounds in this catalogue. It also binds the insulin receptor weakly, and that cross-reactivity is a persistent complication in interpreting experiments.
The defining feature is not the receptor but the binding proteins. Six IGF binding proteins bind IGF-1 with affinity comparable to or greater than the receptor's, and the great majority of circulating IGF-1 is held in complex with them. They are not passive carriers: they determine availability, extend half-life from minutes to hours, and are themselves regulated. Free IGF-1 is a small fraction of total IGF-1, and the two are different quantities.
What do the two modifications actually change?
The R3 is a substitution at position three, glutamate to arginine, which sharply reduces affinity for the binding proteins. The Long is a 13-residue extension at the N-terminus, which further reduces that affinity and adds stability. Together they produce a molecule that remains largely unbound where the native form would be sequestered, and whose half-life is extended because it is not being cleared through the same routes. The receptor affinity is broadly retained — the modifications target the binding proteins, not the receptor.
Why is reduced binding-protein affinity the point?
Because in most experimental systems the binding proteins are a confound rather than a subject. Cultured cells secrete their own IGFBPs into the medium, so adding native IGF-1 to a culture means an unknown fraction is captured before it reaches a receptor — and that fraction varies with cell type, density and how long the medium has been conditioned. The nominal concentration and the available concentration diverge in a way that is not measured. An analogue that largely escapes that capture makes the delivered amount closer to the intended amount, which is why LR3 is the common form in cell work.
The comparison problem
Because the two forms differ in availability rather than in receptor affinity, experiments comparing them are easy to misread.
| IGF-1 | IGF-1 LR3 | |
|---|---|---|
| Length | 70 residues | 83 residues |
| IGFBP affinity | High | Substantially reduced |
| Receptor affinity | High | Broadly retained |
| Free fraction in culture | Variable, often small | Largely free |
| Apparent potency | Depends on the medium | More consistent |
The last row is the trap. LR3 frequently appears more potent than native IGF-1 in cell culture, and that difference is mostly an availability effect rather than a receptor effect. Reporting it as greater potency, without accounting for what the medium's binding proteins did to the native form, describes the assay rather than the molecules.
Can potency figures for IGF-1 analogues be compared across papers?
Rarely, and less reliably than for most compounds. An EC50 here depends on the cell line, the receptor expression level, the serum content of the medium — serum carries binding proteins — and how long the medium was conditioned before the experiment. Two laboratories can report honest figures differing by an order of magnitude for the same molecule. Comparisons are meaningful within a single paper where every condition was shared, and unreliable between papers. This is the same problem that makes incretin EC50 values untransportable, with an extra variable on top.
Does the insulin receptor cross-reactivity matter?
It depends on the readout and it is worth deciding in advance. IGF-1 binds the insulin receptor with much lower affinity than its own, so at low concentrations the cross-talk is minor. At high concentrations, or in cells expressing hybrid receptors assembled from both, the separation breaks down and an effect attributed to IGF-1 receptor signalling may be partly insulin receptor signalling. Where the distinction matters, a selective inhibitor or a receptor-null system is what settles it — the concentration alone does not.
Handling
At 83 residues this is a small protein rather than a short peptide, and it behaves like one. It has a defined structure with three disulphide bridges, which means it can be denatured — a property most peptides in this catalogue do not have. Extremes of pH, heat, vigorous agitation and repeated freeze–thaw can unfold it irreversibly, and an unfolded molecule does not simply refold on dilution.
Two consequences. Foaming is a real hazard rather than a cosmetic one: the air–liquid interface denatures folded proteins, so swirl and never shake. And a carrier protein — typically BSA at low concentration — is commonly added to working dilutions, because at nanogram concentrations losses to the tube wall can exceed what remains in solution.
Do the disulphide bridges change how it should be stored?
They make reducing agents a genuine hazard rather than an inconvenience. DTT and β-mercaptoethanol will reduce the bridges, and the molecule loses its fold along with them — a change that does not reverse when the reducing agent is removed. The three bridges define the structure, so anything that breaks them destroys the protein rather than modifying it. Buffers should be checked for reducing agents before use, which is not a habit that carries over from working with unstructured peptides, where free thiols mostly cause aggregation rather than loss of function. With three bridges there are fifteen ways to pair them, and mass cannot tell which one formed.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
